Skip to main content

SELLAS Life Sciences Group, Inc.

SLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001390478

No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding SELLAS Life Sciences Group, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of SLS: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders3129−2
Shares1.55M1.90M+344.7K (+22.2%)
Value$13.3M$21.3M+$8.03M (+60.6%)

New holders (5)

Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to SLS in Q2 2021
InstitutionSharesValue% of portfolio
Bank of Montreal109,282$1.43M0.00%
State Street Corp37,468$416.0K0.00%
D. E. Shaw & Co., Inc.32,114$356.0K0.00%
JPMorgan Chase & Co876$10.0K0.00%
Royal Bank of Canada400$4.00K0.00%

Sold out (7)

Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.

Institutions that sold out of SLS in Q2 2021
InstitutionShares, Q1 2021Value, Q1 2021
Nomura Holdings Inc131,500$1.11M
Ikarian Capital, LLC48,053$410.0K
Group One Trading, L.P.27,237$233.0K
Virtu Financial LLC14,593$125.0K
Bank of America Corp400$3.00K
Sowell Financial Services LLC10$0
Core Wealth Advisors, Inc.30$0